HISOAR(002099)2025-01-21 10:40Financial Performance - The estimated net profit attributable to shareholders for 2024 is expected to be a loss of between 25,000 and 35,000 million yuan, compared to a loss of 42,005.59 million yuan in the same period last year [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be a loss of between 27,000 and 39,000 million yuan, compared to a loss of 34,065.95 million yuan in the same period last year [3]. - The basic earnings per share is expected to be a loss of between 0.15 and 0.22 yuan per share, compared to a loss of 0.26 yuan per share in the same period last year [3]. - The company plans to recognize impairment losses on fixed assets and goodwill totaling between 23,000 and 30,000 million yuan, which will reduce the net profit attributable to shareholders by the same amount [5]. Industry Challenges - The pharmaceutical and chemical industry is experiencing weak downstream demand and continuous price declines, leading to intensified competition and lower operating performance for the company [6]. Strategic Initiatives - The company is advancing its strategic plans, including collaborations on the Peinan series and expanding CMO/CDMO projects, while also initiating overseas registration for some new products [6]. - The company has seen a significant revenue increase from the collection of Voglibose tablets after winning the bidding [6]. - The company aims to enhance internal management, optimize product structure, and improve efficiency to achieve better development in 2025 [6]. Investor Guidance - The financial data for the 2024 fiscal year will be detailed in the annual report, and investors are advised to make cautious decisions [7].